Skip to content

Feed Screener Search Methodology

SEC · FI · BAFIN · AFM · AMF

Pricing Sign in

InsiderLens

Statistics predict. AI explains.

Insider transactions from public regulatory disclosures, aggregated and enriched with deterministic statistical signals. Not investment advice.

Sources

SEC EDGAR · US
FINANSINSPEKTIONEN · SE
BAFIN · DE
AFM · NL
AMF · FR

Product

Methodology
Privacy notice
Object to processing

Feed Screener Search Methodology

Pricing Sign in

ACORN CAPITAL ADVISORS GP, LLC — OnKure Therapeutics, Inc. insider: 2 transactions · InsiderLens

Home / Insiders / ACORN CAPITAL ADVISORS GP, LLC

ACORN CAPITAL ADVISORS GP, LLC

10% owner at OnKure Therapeutics, Inc. · on record since Oct 9, 2024

Insider trading activity of ACORN CAPITAL ADVISORS GP, LLC

Transactions on record: 2; since May 19, 2025

Open-market buys: 2; $2.6M

Open-market sells: 0

Companies traded: 1; last filing May 19, 2025

Figures computed from official regulatory filings — methodology.

Companies where ACORN CAPITAL ADVISORS GP, LLC has traded

OnKure Therapeutics, Inc.2 tx · $2.6M · May 19, 2025

Track record of ACORN CAPITAL ADVISORS GP, LLC

Insufficient history for a statistical track record (fewer than 5 open-market buys).

Transaction history of ACORN CAPITAL ADVISORS GP, LLC

Co-insiders of ACORN CAPITAL ADVISORS GP, LLC

Access Industries Holdings LLCOnKure Therapeutics, Inc.
ACCESS INDUSTRIES MANAGEMENT, LLCOnKure Therapeutics, Inc.
ACORN BIOVENTURES 2, L.P.OnKure Therapeutics, Inc.
ACORN BIOVENTURES, L.P.OnKure Therapeutics, Inc.
Acorn Capital Advisors GP 2, LLCOnKure Therapeutics, Inc.
Agresta SamuelOnKure Therapeutics, Inc.
AI Biotechnology LLCOnKure Therapeutics, Inc.

This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →

BASKETT FORESTOnKure Therapeutics, Inc.

Blavatnik LenOnKure Therapeutics, Inc.

Blunt Roshawn A.OnKure Therapeutics, Inc.

Cardon LonOnKure Therapeutics, Inc.

Carruthers R MichaelOnKure Therapeutics, Inc.

Chen BihuaOnKure Therapeutics, Inc.

Cormorant Asset Management, LPOnKure Therapeutics, Inc.

Cormorant Global Healthcare Master Fund, LPOnKure Therapeutics, Inc.

Cormorant Private Healthcare Fund III LPOnKure Therapeutics, Inc.

Cormorant Private Healthcare Fund IV LPOnKure Therapeutics, Inc.

Cormorant Private Healthcare Fund V LPOnKure Therapeutics, Inc.

Cruse MichaelOnKure Therapeutics, Inc.

Dorenbaum AlejandroOnKure Therapeutics, Inc.

Dube Eric MOnKure Therapeutics, Inc.

FLESHER GREGORY J.OnKure Therapeutics, Inc.

Florence Anthony A. Jr.OnKure Therapeutics, Inc.

GREY MICHAEL GOnKure Therapeutics, Inc.

Hall AshleyOnKure Therapeutics, Inc.

Harrison Kenneth Ph.D.OnKure Therapeutics, Inc.

Hartley DylanOnKure Therapeutics, Inc.

Hoelscher Paul W.OnKure Therapeutics, Inc.

Hove Anders DOnKure Therapeutics, Inc.

Jansen Valerie MalyvanhOnKure Therapeutics, Inc.

Jindal Vineet R.OnKure Therapeutics, Inc.

Johnson Wendy S.OnKure Therapeutics, Inc.

Kordel JohanOnKure Therapeutics, Inc.

Lam JenniferOnKure Therapeutics, Inc.

Leonard Braden MichaelOnKure Therapeutics, Inc.

Leverone Jason A.OnKure Therapeutics, Inc.

Makhzoumi MohamadOnKure Therapeutics, Inc.

MAKOWER JOSHUAOnKure Therapeutics, Inc.

Manke IsaacOnKure Therapeutics, Inc.

Mathers Edward TOnKure Therapeutics, Inc.

Muralidhar BaliOnKure Therapeutics, Inc.

NEA 15 GP, LLCOnKure Therapeutics, Inc.

NEA Partners 15, L.P.OnKure Therapeutics, Inc.

New Enterprise Associates 15, L.P.OnKure Therapeutics, Inc.

Novo A/SOnKure Therapeutics, Inc.

O'Donnell NiallOnKure Therapeutics, Inc.

Phillips Andrew JohnOnKure Therapeutics, Inc.

Ratcliffe LiamOnKure Therapeutics, Inc.

RiverVest Venture Fund III, L.P.OnKure Therapeutics, Inc.

RiverVest Venture Fund III (Ohio), L.P.OnKure Therapeutics, Inc.

Company	Filed	Type	Qty	Price	Value · USD	Src
OnKure Therapeutics, Inc.	May 19, 2025	Buy	1,129,730	1.85 USD	$2.1M	SEC
OnKure Therapeutics, Inc.	May 19, 2025	Buy	270,270	1.85 USD	$500K	SEC